ABBV · News · 20261107N

Drug Pricing and Tariff Relief

AbbVie Inc. · 2026-11-07 · Importance 40 · Surprise 42

A report says the Inflation Reduction Act (IRA) could create a pricing headwind for AbbVie’s psychiatry drug Vraylar in 2027. It says continued growth from Skyrizi and Rinvoq will be important to offset the anticipated impact, but provides no dollar estimate of the pricing effect. The report also says AbbVie is challenging IRA selection of Botox and that a federal court ruled in AbbVie’s favor, subject to appeal.

Key facts

• AbbVie is actively fighting IRA selection for Botox, and a federal court ruled in its favor; the matter is subject to appeal. source
• IRA pricing on AbbVie's psychiatry drug Vraylar is identified as a potential headwind in 2027. source